The Stanford University School of Medicine, together with privately-held SanBio Inc, have started a Phase 1/2a trial of an allogeneic cell therapy on patients with stable deficits resulting from a stroke. ---Subscribe to MedNous to access this article--- Regenerative Medicine Company News
